Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated Type 2 Diabetes Mellitus

Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated T2DM Patients in Chinese Population

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01372852

Enrollment

300

Registered

2011-06-14

Start date

2010-05-31

Completion date

2011-12-31

Last updated

2011-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Diabetes mellitus

Brief summary

The objective of present study were to compare plasma adiponectin isoform status, their bioactivities newly diagnosed Chinese with healthy volunteer.

Detailed description

Adiponectin, circulates as trimer, hexamer and high molecular weight form (HMW) in human blood, is a promising biomarker for indication diabetes and cardiovascular disease. Both adiponectin complexes concentration and their bioactivities are decreased in pathological state. Disulﬁde-bond A oxidoreductase-like protein (DsbA-L) is a key regulator for adiponectin biosynthesis and its expression level is down-regulated in obese mice and humans. However, the alteration of circulating adiponectin multimers distribution, their bioactivities and adiponectin regulator, DsbA-L level, in newly diagnosed Chinese type 2 diabetes patients are unknown. The objective of present study were to compare plasma adiponectin isoform status, their bioactivities and DsbA-L concentration in newly diagnosed Chinese with healthy volunteer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Having a diabetic history within 12 months * BMI smaller than 30kg/m2

Exclusion criteria

* Having any kinds of treatment affecting glucose * pregnant * uncontrolled hypertension, active cardiac disease, or other major liver, kidney disease

Design outcomes

Primary

Measure	Time frame
plasma adiponectin concentration, isoform distribution and activity.	participants will be followed for the duration of hospital stay, an expected average of 1 week

Countries

China

Contacts

Primary ContactLing Tao, M.D Ph.D

lingtao2006@gmail.com+86-15002955798

Outcome results